High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S. IPO on September 21 after raising money from NVIDIA Corporation (NASDAQ:NVDA) and Qatar Investment Authority, and the same day announced a multi-year research collaboration with AbbVie Inc. (NYSE:ABBV). Iambic will use its AI platform to […]
LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.
Kailera Therapeutics raised one of the biggest obesity biotech IPOs in recent memory, then watched its stock drop nearly 30%. Now several of the world's largest drugmakers have a compelling reason to make a move before pivotal trial data arrives.
Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.
The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.
AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution
AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.
Strong biotech returns, major pharma acquisitions and new IPO filings are reshaping the 2026 U.S. listing market.
There's no need to panic.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the Top 10 Hot Stocks with the Highest Upside Potential. On June 23, H.C. Wainwright reaffirmed its Buy rating on Oruka Therapeutics, Inc. (NASDAQ:ORKA) with a price target of $120 on the stock. This update comes after AbbVie announced that it is acquiring Apogee Therapeutics. AbbVie said that […]
AbbVie knows how to plan ahead.
With a 5-Year Average Dividend Growth Rate of 6.33%, AbbVie Inc. (NYSE:ABBV) is included among the Top 11 Dividend Kings to Buy for Safe Dividend Growth. On June 22, Wells Fargo maintained an Overweight rating on AbbVie Inc. (NYSE:ABBV). It also set a $260 price target on the shares. The firm said AbbVie’s reported bid […]
Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the 10 Stocks Paying Off Big Time. Apogee Therapeutics soared to a fresh all-time high on Monday, as investors gobbled up shares following announcements that it is set to be acquired by pharmaceutical giant AbbVie Inc. at a 49 percent premium. In a joint statement on the same […]
The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.